<DOC>
	<DOCNO>NCT00974792</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer cell growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cell-killing substance . Giving one drug ( combination chemotherapy ) together rituximab may kill cancer cell . PURPOSE : This phase II trial study well give combination chemotherapy together rituximab work treat patient diffuse large B-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Rituximab Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response rate patient high- high/intermediate-risk diffuse large B-cell lymphoma treat CODOX-M/IVAC comprise cyclophosphamide , doxorubicin hydrochloride , vincristine sulfate , methotrexate , ifosfamide , etoposide phosphate , cytarabine rituximab . Secondary - Determine toxicity regimen patient . - Determine progression-free survival patient treat regimen . OUTLINE : This multicenter study . Patients receive rituximab IV day 1 11 CODOX-M comprise doxorubicin hydrochloride IV day 1 , cyclophosphamide IV day 1-5 , vincristine sulfate IV day 1 8 , methotrexate IV 12 hour day 10 , leucovorin calcium IV orally every 3-6 hour begin 24-36 hour methotrexate . Patients also receive CNS prophylaxis comprise cytarabine intrathecally ( IT ) day 1 3 methotrexate IT day 15 . Patients high-risk disease receive additional dose cytarabine IT day 5 methotrexate IT day 17 . Patients also receive pegfilgrastim subcutaneously ( SC ) day 11 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . After completion CODOX-M course 1 , patient receive rituximab IV day 1** IVAC comprise etoposide phosphate IV 1 hour ifosfamide IV 1 hour day 1-5 , cytarabine IV 3 hour ( every 12 hour ) day 1 2 , methotrexate IT day 5 . Patients high-risk disease receive cytarabine IT day 7 9 . Patients also receive pegfilgrastim SC day 7 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . NOTE : **Patients high-risk disease also receive rituximab IV day 21 42 day 1 course 4 ( IVAC ) . Treatment R-CODOX-M R-IVAC repeat every 28 day alternatively 2 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically . Peer Reviewed Funded Endorsed Cancer Research UK .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diffuse large Bcell nonHodgkin lymphoma International Prognostic Index ( IPI ) score highintermediate ( score = 3 ) OR high ( score = 4 5 ) , define : Stage III IV disease Raised lactic dehydrogenase poor performance status ( WHO performance status 24 ) All morphological variant include Bcell nature proliferation must verify positive antiCD20 antibody ( i.e. , CD20positive disease ) No Tcell lymphoma No history treat nontreated indolent lymphoma Patients newly diagnose large Bcell lymphoma small cell infiltration bone marrow lymph node may allow PATIENT CHARACTERISTICS : See Disease Characteristics Life expectancy &gt; 3 month ANC &gt; 1,500/mm^3* Platelet count &gt; 100,000/mm^3* Serum creatinine &lt; 150 μmol/L* Serum bilirubin &lt; 35 μmol/L* AST and/or ALT &lt; 2.5 time upper limit normal* NOTE : *Unless attribute bone marrow infiltration lymphoma . Fertile patient must use effective contraception Normal MUGA echocardiogram without area abnormal contractility LVEF ≥ 50 % test patient meet 1 follow criterion : History diabetes Prior cardiac disease , hypertension , abnormal rest ECG No history heart failure uncontrolled angina pectoris No cardiac contraindication doxorubicin hydrochloride ( e.g. , abnormal contractility echocardiography MUGA ) No neurological contraindication vincristine sulfate ( e.g. , preexist diabetic neuropathy ) No concurrent uncontrolled medical condition No serious active disease No general status , accord investigator , allow administration 2 course CODOXM/IVAC No active malignant disease within past 10 year except curatively treat basal squamous cell carcinoma skin carcinoma situ uterine cervix No positive serology HIV hepatitis B C No medical psychiatric condition compromise patient 's ability give inform consent PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy , radiotherapy , investigational drug diffuse large Bcell nonHodgkin lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>